Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect

scientific article published on 01 October 1999

Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1046/J.1365-2141.1999.01673.X
P698PubMed publication ID10520041

P2093author name stringH Suzuki
M Shibata
I Tanaka
A Yoshioka
H Nakai
M Shima
J C Giddings
K Nogami
S Morichika
E L Saenko
D Scandella
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)196-203
P577publication date1999-10-01
P1433published inBritish Journal of HaematologyQ4970200
P1476titleIdentification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect
P478volume107

Reverse relations

cites work (P2860)
Q41966601A factor VIII-derived peptide enables von Willebrand factor (VWF)-binding of artificial platelet nanoconstructs without interfering with VWF-adhesion of natural platelets
Q37382199B-cell and T-cell epitopes in anti-factor VIII immune responses
Q37378510Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.
Q36412125Characterization of factor VIII inhibitors
Q30481770Covalent inactivation of factor VIII antibodies from hemophilia A patients by an electrophilic FVIII Analog
Q45855091High throughput mutation screening of the factor VIII gene (F8C) in hemophilia A: 37 novel mutations and genotype-phenotype correlation
Q36317966Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.
Q31056138Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8.
Q80273707Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain

Search more.